Cogent Biosciences, Inc. COGT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $75.37M+19.6% | $75.56M+21.8% | $68.99M+8.4% | $62.2M+14.6% | $63.03M+19.6% | ||
| $28.24M+137% | $23.93M+105% | $14.37M+21.7% | $13.38M+32.6% | $11.9M+22.7% | ||
| $103.61M+38.3% | $99.49M+34.9% | $83.36M+10.5% | $75.58M+17.4% | $74.93M+20.1% | ||
| -$103.61M-38.3% | -$99.49M-34.9% | -$83.36M-10.5% | -$75.58M-17.4% | -$74.93M-20.1% | ||
| $1.21M— | $1.29M— | $1.46M— | $314K— | $0— | ||
| $7.61M+158% | $5.48M+41.9% | $3.89M-18.7% | $2.37M-56.0% | $2.95M-27.2% | ||
| $6.26M+112% | —— | $2.43M-49.3% | $2.05M-62.2% | $2.95M-27.3% | ||
| —— | -$1.8M— | -$1.8M— | -$1.8M— | -$1.8M— | ||
| -$97.35M-35.2% | -$102.49M-50.9% | -$80.93M-14.6% | -$73.53M-24.7% | -$71.99M-23.4% | ||
| -$0.53-1.9% | -$0.61-22.0% | -$0.50+3.8% | -$0.53-23.3% | -$0.52-6.1% | ||
| -$0.53-1.9% | -$0.61-22.0% | -$0.50+3.8% | -$0.53-23.3% | -$0.52-6.1% | ||
| 162.2M+43.1% | 128.9M+24.1% | 137.6M+24.9% | 114.5M+15.3% | 113.3M+19.5% | ||
| 162.2M+43.1% | 128.9M+24.1% | 137.6M+24.9% | 114.5M+15.3% | 113.3M+19.5% | ||
| -$98.12M-35.8% | -$102.35M-49.7% | -$80.74M-16.1% | -$73.68M-24.7% | -$72.27M-23.3% | ||
| -$135K— | —— | —— | —— | -$0— | ||
| -$770K-172% | —— | $195K-82.1% | -$151K+1.3% | -$283K+0.7% | ||
| -$770K-172% | —— | $195K-82.1% | -$151K+1.3% | -$283K+0.7% | ||
| -$140K-2,700% | -$6K-100% | -$3K-400% | -$6K-114% | -$5K-400% | ||
| -$103.61M-38.3% | -$99.49M-34.9% | -$83.36M-10.5% | -$75.58M-17.4% | -$74.93M-20.1% | ||
| -$102.98M-38.6% | -$98.85M-35.2% | -$82.71M-10.6% | -$74.93M-17.5% | -$74.29M-20.2% | ||
| -$102.98M-38.6% | -$98.85M-35.2% | -$82.71M-10.6% | -$74.93M-17.5% | -$74.29M-20.2% | ||
| -$103.61M-38.3% | -$99.49M-34.9% | -$83.36M-10.5% | -$75.58M-17.4% | -$74.93M-20.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cogent Biosciences, Inc.'s revenue?
- Cogent Biosciences, Inc. (COGT) generated $7.9M in revenue over the trailing twelve months, down 65.0% year over year.
- Is Cogent Biosciences, Inc. profitable?
- Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $354.3M over the trailing twelve months, a -950.4% net margin.
- What is Cogent Biosciences, Inc.'s earnings per share?
- Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.
- Where does Cogent Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
